Lv1
20 积分 2026-02-05 加入
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management
23小时前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
1天前
已完结
Evaluating the Immunogenicity Risk of Protein Therapeutics by Augmenting T Cell Epitope Prediction with Clinical Factors
3天前
已完结
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
7天前
已完结
Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis
29天前
已关闭
Mechanisms and therapeutic insights into MASH-associated fibrosis
1个月前
已完结
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
1个月前
已完结
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American Heart Association Scientific Sessions
1个月前
已完结
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
1个月前
已完结
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
1个月前
已完结
皖公网安备34019202002308
